No Data
No Data
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival -- Barrons.com
By Josh Nathan-Kazis A second failure of a late-stage trial testing a gene therapy to treat Duchenne muscular dystrophy is bad news for patients, but Wall Street analysts say it could be good new for
Pfizer's Gene-therapy Trial Failure Boosts Sarepta's Stock
By Eleanor Laise Sarepta's gene therapy for Duchenne muscular dystrophy could soon get expanded label from FDA Shares of Sarepta Therapeutics Inc. (SRPT) gained 4% premarket on Thursday after a pote
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
Piper Sandler analyst Biren Amin maintains $Solid Biosciences(SLDB.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 41.4% and
Solid Biosciences(SLDB.US) Director Buys US$8,441.62 in Common Stock
$Solid Biosciences(SLDB.US)$ Director Kahn Clare purchased 1,100 shares of common stock on Jun 7, 2024 at an average price of $7.6742 for a total value of $8,441.62.Source: Announcement What is statem
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and card
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth